Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant ...

Oncolytics Biotech has aligned with the FDA on a registrational pathway for expanding its REO 033 study into a pivotal trial for second-line RAS-mutant, microsatellite stable metastatic colorectal cancer, with potential accelerated approval based on objective response rate and progression-free survival supporting full approval.

This Wire brief sits within Fusion42's coverage of Biotech.